DGAP-News

Press Release 4SC AG: BEYOND RESEARCH initiative of 4SC Discovery and CRELUX reaches first milestone in drug discovery project for Helmholtz Zentrum München

DGAP-News: 4SC AG / Key word(s): Alliance
Press Release 4SC AG: BEYOND RESEARCH initiative of 4SC Discovery and
CRELUX reaches first milestone in drug discovery project for Helmholtz
Zentrum München

13.01.2015 / 07:30

---------------------------------------------------------------------

Press Release

Drug research to be strengthened further in the Munich business area:

BEYOND RESEARCH initiative of 4SC Discovery and CRELUX reaches first
milestone in drug discovery project for Helmholtz Zentrum München

- Compounds for inhibiting oxygen radicals and associated signalling
pathways optimised for developing innovative therapies for degenerative
diseases.

- Bavarian Ministry of Economic Affairs funding collaboration that will
promote the commercial exploitation of a scientific product idea from
Helmholtz Zentrum München.

- BEYOND RESEARCH initiative of 4SC Discovery, CRELUX and Prefound GmbH
to provide technology and expertise for transforming drug research from
academic institutions into commercially exploitable pharmaceutical
products in the Munich area.

Planegg-Martinsried and Munich, Germany, 13 January 2015 - 4SC Discovery
GmbH, a subsidiary of the biotechnology company 4SC AG (Frankfurt, Prime
Standard: VSC) and its partner CRELUX GmbH have successfully completed the
first stage of a collaboration with the RỌScue Therapeutics working group
at the Munich-based Helmholtz Zentrum München in the field of research and
drug discovery of new compounds for treatment of degenerative diseases. The
second stage of the project has been started now.

The work is being performed as part of the BEYOND RESEARCH initiative and
is funded by the Bavarian Ministry of Economic Affairs and Helmholtz
Zentrum München. This is expected to lay the foundations for a possible
later spin-off of RỌScue Therapeutics. The BEYOND RESEARCH initiative
formed by the biotech companies 4SC Discovery GmbH and CRELUX GmbH, the
start-up consultancy firm Prefound GmbH and the transMedChem consulting
firm will provide technology and expertise for translating biomedical
science from academic institutions into commercially exploitable
pharmaceutical products in the Munich area.

Within the scope of the collaboration, several compounds will be analysed
and optimised with the objective of generating a pharmaceutical development
candidate that can subsequently be developed further into an effective
therapy for degenerative diseases. The compounds studied inhibit certain
signalling pathways in cells which are triggered by the release of free
oxygen radicals and can lead to tissue damage in patients. Based on the